ADHD has a biological basis, but there is no single ADHD brain pattern, neurotransmitter problem, gene, or scan that explains every person with ADHD.
The strongest current evidence points to a highly heritable, polygenic neurodevelopmental condition involving many interacting biological pathways and distributed brain networks. Research is improving quickly, but much of what is found at the group level cannot yet be used to diagnose or choose treatment for an individual person.
ADHD Has a Strong Genetic Component
Family and twin studies consistently show that ADHD runs in families. Recent genomic research continues to support a substantial genetic contribution.
ADHD is polygenic. That means risk is influenced by many genetic variants, most with very small individual effects. Both common and rare variants appear to contribute.
A 2025 genome-wide association meta-analysis identified 39 independent loci associated with ADHD diagnosis when symptom data and diagnostic samples were combined. A 2025/2026 whole-exome study also identified rare variants that can contribute substantial risk in a smaller proportion of people.
van der Laan and colleagues, 2025
Demontis and colleagues, 2025/2026
There Is No Genetic Test That Diagnoses ADHD
The original workshop notes correctly emphasized that genetics is not clinically precise enough to diagnose ordinary ADHD or choose a specific stimulant, dose, or treatment plan.
Current genomic research is useful for understanding ADHD biology and population-level risk. It does not provide a routine clinical blood or saliva test that can tell someone:
- whether they have ADHD
- which ADHD medication will work best
- what dose they should take
- how severe their ADHD will be
ADHD diagnosis remains clinical and is based on developmental history, symptoms, impairment, context, and differential diagnosis.
ADHD Does Not Come From One Brain Area
Older explanations sometimes locate ADHD mainly in the prefrontal cortex or describe one specific brain pathway as “the ADHD pathway.” That is too simple.
Attention, inhibition, working memory, motivation, reward learning, time processing, task switching, and emotional regulation depend on distributed networks that interact across the brain.
Neuroimaging studies do find group-level differences in structure, activity, and connectivity. But findings vary across studies and across people with ADHD.
A brain scan cannot currently diagnose an individual person with ADHD. Group averages are not the same as an individual biomarker.
What About Dopamine?
Dopamine is important in ADHD research, especially in reward learning, reinforcement, motivation, and the mechanisms of stimulant medication.
But the common phrase “ADHD is caused by low dopamine” is not an accurate summary of current science.
PET research in adults has reported differences in dopamine-related markers in some studies, but findings for dopamine transporters and receptors have not been consistent enough to define a single ADHD dopamine abnormality. Serotonin and norepinephrine findings are also mixed or less reproducible.
A more accurate explanation is:
ADHD involves differences in brain systems that use dopamine, norepinephrine, and other signaling systems, but there is no single chemical deficiency that explains ADHD.
Serotonin systematic review, 2025
Reward and Motivation Are Part of the Picture
The workshop notes were useful in emphasizing that ADHD is not only about “paying attention.” Research also examines reward processing, motivation, reinforcement learning, and the effort required to sustain behavior when rewards are delayed or unclear.
This does not mean ADHD people cannot be motivated. It means that motivation and performance are influenced by the way a task is structured, when reward is available, how much effort it requires, and how much support the environment provides.
That helps explain why the same person may focus intensely in one situation and struggle to begin in another.
How Stimulant Medication Fits In
Amphetamine- and methylphenidate-based stimulants alter catecholamine signaling, including dopamine and norepinephrine pathways.
For many people, stimulant medication can make it easier to sustain attention, inhibit responses, organize behavior, and persist with tasks. Medication response varies, and improvement does not prove that ADHD was caused by a dopamine deficiency.
The older workshop notes also captured an important real-world effect: treatment can change a person’s feedback environment.
When tasks become more manageable, a person may experience:
- more completion
- fewer preventable mistakes
- more useful feedback
- less shame
- greater confidence approaching the next task
The reverse can also occur when a person is repeatedly expected to perform without adequate support:
difficulty → missed expectations → criticism or self-criticism → avoidance → less confidence → more difficulty
That cycle is psychological and social as well as biological.
ADHD Biology Is Not Isolated From the Rest of the Body
Sleep, stress, illness, pain, hormones, medications, nutrition, physical activity, and environmental demands can all affect attention and executive functioning.
These factors do not “cause” ordinary ADHD in a simple way, but they can change how much difficulty a person experiences on a given day or life stage.
This is one reason support should not focus only on the brain. It can also include sleep treatment, movement, workload changes, sensory accommodations, environmental fit, treatment of co-occurring conditions, and attention to hormonal transitions.
ADHD Often Overlaps With Other Conditions
ADHD commonly co-occurs with anxiety, depression, sleep disorders, learning differences, autism, and other neurodevelopmental or mental-health conditions.
Some of this overlap is also visible genetically. Large genomic studies find shared genetic influences between ADHD and other psychiatric and neurodevelopmental conditions. Shared genetic risk does not mean the conditions are the same or that one inevitably causes another.
What We Still Do Not Know
ADHD neuroscience is advancing quickly, but several limits are important:
- there is no single ADHD gene
- there is no single ADHD neurotransmitter abnormality
- there is no diagnostic brain scan
- genetic findings do not yet tell us the best medication for an individual person
- group-level brain differences do not describe every person with ADHD
- biological findings do not tell us how much difficulty a person will experience in a particular environment
A More Useful Way to Use Neurobiology
Neurobiology can help move us away from explanations based on laziness, character, or lack of effort.
But biology should not become another oversimplified story.
A useful clinical question is:
What biological, psychological, environmental, and relational conditions make it easier or harder for this person to use their attention, energy, working memory, motivation, and regulation?
That leaves room for neuroscience without reducing a person to a brain scan or dopamine level.
Sources
- van der Laan et al. Genome-wide association meta-analysis of childhood ADHD symptoms and diagnosis, 2025
- Haavik. Genomics of ADHD: What the Clinician Needs to Know, 2025
- Demontis et al. Rare genetic variants confer a high risk of ADHD, 2025/2026
- Positron emission tomography studies in adult ADHD, 2022
- Role of serotonin in the neurobiology of ADHD, 2025
Kristen McClure, MSW, LCSW · Flourishing Women LLC
This is educational information and is not medical advice.